ES2918249T3 - Biomarcadores inflamatorios para predecir la capacidad de respuesta al compuesto FGF-18 - Google Patents
Biomarcadores inflamatorios para predecir la capacidad de respuesta al compuesto FGF-18 Download PDFInfo
- Publication number
- ES2918249T3 ES2918249T3 ES18782012T ES18782012T ES2918249T3 ES 2918249 T3 ES2918249 T3 ES 2918249T3 ES 18782012 T ES18782012 T ES 18782012T ES 18782012 T ES18782012 T ES 18782012T ES 2918249 T3 ES2918249 T3 ES 2918249T3
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- fgf
- compound
- cartilage
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000003977 fibroblast growth factor 18 Human genes 0.000 title claims abstract description 216
- 108090000370 fibroblast growth factor 18 Proteins 0.000 title claims abstract description 216
- 150000001875 compounds Chemical class 0.000 title claims abstract description 129
- 239000000090 biomarker Substances 0.000 title claims abstract description 79
- 230000002757 inflammatory effect Effects 0.000 title description 11
- 230000004043 responsiveness Effects 0.000 title description 4
- 238000011282 treatment Methods 0.000 claims abstract description 220
- 208000015100 cartilage disease Diseases 0.000 claims abstract description 44
- 206010061762 Chondropathy Diseases 0.000 claims abstract description 34
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 30
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 30
- 210000000845 cartilage Anatomy 0.000 claims description 72
- 238000000034 method Methods 0.000 claims description 53
- 230000035945 sensitivity Effects 0.000 claims description 45
- 201000008482 osteoarthritis Diseases 0.000 claims description 39
- 206010007710 Cartilage injury Diseases 0.000 claims description 19
- 208000013201 Stress fracture Diseases 0.000 claims description 12
- 102000037865 fusion proteins Human genes 0.000 claims description 10
- 108020001507 fusion proteins Proteins 0.000 claims description 10
- 238000001356 surgical procedure Methods 0.000 claims description 10
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 9
- 210000001188 articular cartilage Anatomy 0.000 claims description 8
- 102100032752 C-reactive protein Human genes 0.000 claims description 7
- 206010017076 Fracture Diseases 0.000 claims description 6
- 102000012422 Collagen Type I Human genes 0.000 claims description 4
- 108010022452 Collagen Type I Proteins 0.000 claims description 4
- 102000005741 Metalloproteases Human genes 0.000 claims description 4
- 108010006035 Metalloproteases Proteins 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 230000004071 biological effect Effects 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 229940096422 collagen type i Drugs 0.000 claims description 3
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 230000004044 response Effects 0.000 abstract description 42
- 210000002700 urine Anatomy 0.000 abstract description 11
- 238000002560 therapeutic procedure Methods 0.000 abstract description 10
- 210000001179 synovial fluid Anatomy 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 8
- 210000002966 serum Anatomy 0.000 abstract description 8
- 238000003745 diagnosis Methods 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 2
- 238000002203 pretreatment Methods 0.000 abstract 1
- 229950002135 sprifermin Drugs 0.000 description 39
- 239000000902 placebo Substances 0.000 description 34
- 229940068196 placebo Drugs 0.000 description 33
- 230000008859 change Effects 0.000 description 28
- 239000000523 sample Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 19
- 238000002347 injection Methods 0.000 description 18
- 239000007924 injection Substances 0.000 description 18
- 210000003127 knee Anatomy 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 17
- 238000003556 assay Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 208000002193 Pain Diseases 0.000 description 16
- 230000003442 weekly effect Effects 0.000 description 15
- 206010061218 Inflammation Diseases 0.000 description 14
- 230000004054 inflammatory process Effects 0.000 description 14
- 210000000521 femorotibial joint Anatomy 0.000 description 12
- 230000008439 repair process Effects 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000000092 prognostic biomarker Substances 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 108010017322 catch-relaxing peptide (Mytilus) Proteins 0.000 description 9
- 239000012472 biological sample Substances 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 238000002595 magnetic resonance imaging Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000003150 biochemical marker Substances 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 5
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000007717 exclusion Effects 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 230000009266 disease activity Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- 229940124638 COX inhibitor Drugs 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 210000000968 fibrocartilage Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000003116 impacting effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 238000013517 stratification Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 101001034207 Homo sapiens Mitochondrial folate transporter/carrier Proteins 0.000 description 2
- 101000823778 Homo sapiens Y-box-binding protein 2 Proteins 0.000 description 2
- 102100039811 Mitochondrial folate transporter/carrier Human genes 0.000 description 2
- 206010065159 Polychondritis Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000022159 cartilage development Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- 208000024765 knee pain Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- -1 sprifermin) Chemical class 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000008409 synovial inflammation Effects 0.000 description 2
- 229960003989 tocilizumab Drugs 0.000 description 2
- 229960004380 tramadol Drugs 0.000 description 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 206010011219 Costochondritis Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100035308 Fibroblast growth factor 17 Human genes 0.000 description 1
- 108050002074 Fibroblast growth factor 17 Proteins 0.000 description 1
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010060820 Joint injury Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010073853 Osteochondral fracture Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 102400000827 Saposin-D Human genes 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000026317 Tietze syndrome Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 206010071578 autoimmune retinopathy Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000002849 chondrocalcinosis Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000001700 effect on tissue Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003035 hyaline cartilage Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 230000008429 joint-tissue turnover Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012148 non-surgical treatment Methods 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000009169 relapsing polychondritis Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000012488 skeletal system development Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000008354 tissue degradation Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17194169 | 2017-09-29 | ||
| EP18169317 | 2018-04-25 | ||
| PCT/EP2018/076391 WO2019063756A1 (en) | 2017-09-29 | 2018-09-28 | INFLAMMATORY BIOMARKERS FOR PREDICTING REACTIVITY TO FGF-18 COMPOUND |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2918249T3 true ES2918249T3 (es) | 2022-07-14 |
Family
ID=63722379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18782012T Active ES2918249T3 (es) | 2017-09-29 | 2018-09-28 | Biomarcadores inflamatorios para predecir la capacidad de respuesta al compuesto FGF-18 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11467169B2 (enExample) |
| EP (1) | EP3688468B1 (enExample) |
| JP (1) | JP7418324B2 (enExample) |
| CN (1) | CN111164429B (enExample) |
| AU (1) | AU2018343980B2 (enExample) |
| CA (1) | CA3075713A1 (enExample) |
| DK (1) | DK3688468T3 (enExample) |
| ES (1) | ES2918249T3 (enExample) |
| HR (1) | HRP20220737T1 (enExample) |
| HU (1) | HUE058848T2 (enExample) |
| IL (1) | IL273574B2 (enExample) |
| LT (1) | LT3688468T (enExample) |
| PL (1) | PL3688468T3 (enExample) |
| RS (1) | RS63292B1 (enExample) |
| SI (1) | SI3688468T1 (enExample) |
| WO (1) | WO2019063756A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107209177A (zh) | 2015-01-29 | 2017-09-26 | 阿雷斯贸易股份有限公司 | 用于高正电荷蛋白的免疫测定法 |
| CN111164429B (zh) | 2017-09-29 | 2024-08-09 | 默克专利有限公司 | 预测对fgf-18化合物反应性的炎性生物标志物 |
| CN111163791A (zh) | 2017-09-29 | 2020-05-15 | 默克专利有限公司 | 预测对fgf-18化合物反应性的代谢生物标志物 |
| HRP20240665T1 (hr) | 2018-09-10 | 2024-08-16 | Merck Patent Gmbh | Markeri korisni u strategijama obogaćivanja za liječenje osteoartritisa |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9712348B1 (pt) | 1996-10-16 | 2013-06-18 | vetor de expressão, célula de bactéria ou levedura transformada ou transfectada, processo para produzir um polipeptídeo homólogo de fgf, composição farmacêutica, e, processos para estimular ex vivo células progenitoras de miócitos ou miócitos | |
| JP4754823B2 (ja) | 2002-10-07 | 2011-08-24 | ザイモジェネティクス， インコーポレイテッド | Ｆｇｆ１８の投与方法 |
| CA2502926A1 (en) | 2002-11-08 | 2004-05-27 | Linda J. Sandell | Uncoupled collagen synthesis and degradation assays |
| AU2005314438B2 (en) | 2004-12-10 | 2012-03-29 | Zymogenetics, Inc. | FGF18 production in prokaryotic hosts |
| US8224579B2 (en) | 2005-06-17 | 2012-07-17 | The Brigham And Women's Hospital, Inc. | Method of diagnosing osteoarthritis |
| AR062522A1 (es) | 2006-08-25 | 2008-11-12 | Ares Trading Sa | Tratamiento de desordenes en cartilagos |
| JP2009257842A (ja) | 2008-04-14 | 2009-11-05 | Ttc:Kk | 変形性関節症の検査方法及び診断用キット |
| US20100098775A1 (en) | 2008-05-02 | 2010-04-22 | Interleukin Genetics, Inc. | Detecting genetic predisposition to osteoarthritis associated conditions |
| US20090299769A1 (en) | 2008-05-29 | 2009-12-03 | Nordic Bioscience Imaging A/S | Prognostic osteoarthritis biomarkers |
| US20120115137A1 (en) | 2010-08-31 | 2012-05-10 | Kornman Kenneth S | Methods of Predicting Osteoarthritis |
| TWI527590B (zh) | 2011-06-17 | 2016-04-01 | 艾瑞斯貿易公司 | Ｆｇｆ－１８之凍乾調配物 |
| WO2014023704A1 (en) | 2012-08-06 | 2014-02-13 | xARES TRADING S.A. | Prognosis biomarkers in cartilage disorders |
| US10221456B2 (en) | 2012-08-06 | 2019-03-05 | Merck Patent Gmbh | Genetic markers for predicting responsiveness to FPG-18 compound |
| WO2015084883A2 (en) | 2013-12-02 | 2015-06-11 | Abbvie, Inc. | Compositions and methods for treating osteoarthritis |
| CN106029085B (zh) | 2013-12-24 | 2020-08-04 | 阿雷斯贸易股份有限公司 | 木糖葡聚糖凝胶中的fgf-18制剂 |
| SG11201604972TA (en) | 2013-12-24 | 2016-07-28 | Ares Trading Sa | Fgf-18 formulation in alginate/collagen hydrogels |
| MX2016010872A (es) | 2014-02-20 | 2016-11-17 | Merck Patent Gmbh | Regimen de dosificacion del compuesto de factor de crecimiento de fibroblastos 18. |
| LT3107592T (lt) | 2014-02-20 | 2018-12-10 | Merck Patent Gmbh | Implantas, apimantis fgf-18 |
| EP3107591B1 (en) | 2014-02-20 | 2018-04-18 | Merck Patent GmbH | Fgf-18 in graft transplantation and tissue engineering procedures |
| CN107209177A (zh) | 2015-01-29 | 2017-09-26 | 阿雷斯贸易股份有限公司 | 用于高正电荷蛋白的免疫测定法 |
| CN108473491A (zh) | 2015-11-06 | 2018-08-31 | 萨穆梅德有限公司 | 2-(1h-吲唑-3-基)-3h-咪唑并[4,5-c]吡啶以及其抗炎用途 |
| US9983214B2 (en) | 2016-04-15 | 2018-05-29 | Esm Technologies, Llc | Method for evaluating articular joint therapeutics |
| CN111164429B (zh) | 2017-09-29 | 2024-08-09 | 默克专利有限公司 | 预测对fgf-18化合物反应性的炎性生物标志物 |
| CN111163791A (zh) | 2017-09-29 | 2020-05-15 | 默克专利有限公司 | 预测对fgf-18化合物反应性的代谢生物标志物 |
| HRP20240665T1 (hr) | 2018-09-10 | 2024-08-16 | Merck Patent Gmbh | Markeri korisni u strategijama obogaćivanja za liječenje osteoartritisa |
-
2018
- 2018-09-28 CN CN201880063173.4A patent/CN111164429B/zh active Active
- 2018-09-28 AU AU2018343980A patent/AU2018343980B2/en active Active
- 2018-09-28 US US16/650,878 patent/US11467169B2/en active Active
- 2018-09-28 JP JP2020517797A patent/JP7418324B2/ja active Active
- 2018-09-28 WO PCT/EP2018/076391 patent/WO2019063756A1/en not_active Ceased
- 2018-09-28 IL IL273574A patent/IL273574B2/en unknown
- 2018-09-28 HU HUE18782012A patent/HUE058848T2/hu unknown
- 2018-09-28 HR HRP20220737TT patent/HRP20220737T1/hr unknown
- 2018-09-28 LT LTEPPCT/EP2018/076391T patent/LT3688468T/lt unknown
- 2018-09-28 DK DK18782012.1T patent/DK3688468T3/da active
- 2018-09-28 ES ES18782012T patent/ES2918249T3/es active Active
- 2018-09-28 SI SI201830693T patent/SI3688468T1/sl unknown
- 2018-09-28 RS RS20220541A patent/RS63292B1/sr unknown
- 2018-09-28 PL PL18782012.1T patent/PL3688468T3/pl unknown
- 2018-09-28 EP EP18782012.1A patent/EP3688468B1/en active Active
- 2018-09-28 CA CA3075713A patent/CA3075713A1/en active Pending
-
2022
- 2022-09-01 US US17/929,261 patent/US12332250B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111164429B (zh) | 2024-08-09 |
| HRP20220737T1 (hr) | 2022-09-02 |
| RS63292B1 (sr) | 2022-06-30 |
| US11467169B2 (en) | 2022-10-11 |
| DK3688468T3 (da) | 2022-06-20 |
| EP3688468A1 (en) | 2020-08-05 |
| CA3075713A1 (en) | 2019-04-04 |
| LT3688468T (lt) | 2022-06-27 |
| EP3688468B1 (en) | 2022-03-16 |
| US20210231680A1 (en) | 2021-07-29 |
| US12332250B2 (en) | 2025-06-17 |
| US20230258659A1 (en) | 2023-08-17 |
| IL273574A (en) | 2020-05-31 |
| JP2020535423A (ja) | 2020-12-03 |
| IL273574B2 (en) | 2025-01-01 |
| JP7418324B2 (ja) | 2024-01-19 |
| AU2018343980A1 (en) | 2020-04-02 |
| HUE058848T2 (hu) | 2022-09-28 |
| AU2018343980B2 (en) | 2025-04-10 |
| WO2019063756A1 (en) | 2019-04-04 |
| PL3688468T3 (pl) | 2022-07-18 |
| SI3688468T1 (sl) | 2022-08-31 |
| CN111164429A (zh) | 2020-05-15 |
| IL273574B1 (en) | 2024-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2980597T3 (es) | Marcadores útiles en las estrategias de enriquecimiento para el tratamiento de la artrosis | |
| US12332250B2 (en) | Inflammatory biomarkers for predicting responsiveness to FGF-18 compound | |
| US12332251B2 (en) | Metabolic biomarkers for predicting responsiveness to FGF-18 compound | |
| HK40058829B (en) | Markers useful in enrichment strategies for the treatment of osteoarthritis | |
| HK40058829A (en) | Markers useful in enrichment strategies for the treatment of osteoarthritis |